Aytu BioPharma (AYTU)
(Delayed Data from NSDQ)
$2.85 USD
+0.03 (1.06%)
Updated Jul 18, 2024 03:59 PM ET
After-Market: $2.85 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Aytu BioPharma Inc falls in the month of June.
All items in Millions except Per Share data.
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 23 | 19 | 50 | 48 |
Receivables | NA | 29 | 22 | 28 | 5 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 12 | 11 | 16 | 10 |
Other Current Assets | NA | 9 | 8 | 11 | 11 |
Total Current Assets | NA | 73 | 60 | 105 | 75 |
Net Property & Equipment | NA | 2 | 3 | 5 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 59 | 71 | 151 | 77 |
Deposits & Other Assets | NA | 1 | 1 | 0 | 0 |
Total Assets | NA | 136 | 138 | 266 | 153 |
Liabilities & Shareholders Equity | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 13 | 11 | 19 | 12 |
Current Portion Long-Term Debt | NA | 2 | 4 | 28 | 3 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 47 | 44 | 57 | 11 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 7 | 5 | 4 | 2 |
Total Current Liabilities | NA | 69 | 64 | 109 | 28 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 15 | 14 | 7 | 11 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 13 | 13 | 10 | 18 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 97 | 92 | 128 | 58 |
Shareholders Equity | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 343 | 335 | 316 | 215 |
Retained Earnings | NA | -304 | -288 | -178 | -120 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 39 | 46 | 138 | 95 |
Total Liabilities & Shareholder's Equity | NA | 136 | 138 | 266 | 153 |
Total Common Equity | 0 | 39 | 46 | 138 | 95 |
Shares Outstanding | 5.90 | 3.70 | 1.90 | 1.20 | 0.60 |
Book Value Per Share | 0.00 | 10.64 | 24.26 | 114.64 | 158.37 |
Fiscal Year End for Aytu BioPharma Inc falls in the month of June.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 20 | 20 | 20 | 23 |
Receivables | NA | 30 | 29 | 30 | 29 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 13 | 13 | 13 | 12 |
Other Current Assets | NA | 8 | 9 | 8 | 9 |
Total Current Assets | NA | 71 | 71 | 71 | 73 |
Net Property & Equipment | NA | 1 | 1 | 2 | 2 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 54 | 56 | 57 | 59 |
Deposits & Other Assets | NA | 1 | 1 | 1 | 1 |
Total Assets | NA | 129 | 131 | 133 | 136 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 10 | 10 | 14 | 13 |
Current Portion Long-Term Debt | NA | 17 | 1 | 1 | 2 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 44 | 43 | 41 | 47 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 12 | 9 | 9 | 7 |
Total Current Liabilities | NA | 84 | 64 | 65 | 69 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 15 | 15 | 15 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 19 | 20 | 13 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 98 | 98 | 101 | 97 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 346 | 345 | 344 | 343 |
Retained Earnings | NA | -315 | -312 | -312 | -304 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 31 | 33 | 32 | 39 |
Total Liabilities & Shareholder's Equity | NA | 129 | 131 | 133 | 136 |
Total Common Equity | 0 | 31 | 33 | 32 | 39 |
Shares Outstanding | 5.90 | 5.50 | 5.50 | 5.50 | 3.70 |
Book Value Per Share | 0.00 | 5.60 | 5.97 | 5.85 | 10.64 |